DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Glucagon (Glucagon Hydrochloride) - Drug Interactions, Contraindications, Overdosage, etc



GLUCAGON drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.


— If overdosage occurs, nausea, vomiting, gastric hypotonicity, and diarrhea would be expected without causing consequential toxicity. Signs and Symptoms

Intravenous administration of glucagon has been shown to have positive inotropic and chronotropic effects. A transient increase in both blood pressure and pulse rate may occur following the administration of glucagon. Patients taking β-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be transient because of glucagon's short half-life. The increase in blood pressure and pulse rate may require therapy in patients with pheochromocytoma or coronary artery disease.

When glucagon was given in large doses to patients with cardiac disease, investigators reported a positive inotropic effect. These investigators administered glucagon in doses of 0.5 to 16 mg/hour by continuous infusion for periods of 5 to 166 hours. Total doses ranged from 25 to 996 mg, and a 21-month-old infant received approximately 8.25 mg in 165 hours. Side effects included nausea, vomiting, and decreasing serum potassium concentration. Serum potassium concentration could be maintained within normal limits with supplemental potassium.

The intravenous median lethal dose for glucagon in mice and rats is approximately 300 mg/kg and 38.6 mg/kg, respectively.

Because glucagon is a polypeptide, it would be rapidly destroyed in the gastrointestinal tract if it were to be accidentally ingested.

— To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient. Treatment Physicians' Desk Reference (PDR)

In view of the extremely short half-life of glucagon and its prompt destruction and excretion, the treatment of overdosage is symptomatic, primarily for nausea, vomiting, and possible hypokalemia.

If the patient develops a dramatic increase in blood pressure, 5 to 10 mg of phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.

Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of glucagon; it is extremely unlikely that one of these procedures would ever be indicated.


Glucagon is contraindicated in patients with known hypersensitivity to it or in patients with known pheochromocytoma.


  1. 18th ed. Rockville, Maryland: The United States Pharmacopeial Convention, Inc; 1998; I:1512. Drug Information for the Health Care Professional.
  2. Gibbs et al: Use of glucagon to terminate insulin reactions in diabetic children. 1958;43:56-57. Nebr Med J
  3. Cornblath M, et al: Studies of carbohydrate metabolism in the newborn: Effect of glucagon on concentration of sugar in capillary blood of newborn infant. 1958;21:885-892. Pediatrics
  4. Carson MJ, Koch R: Clinical studies with glucagon in children. 1955;47:161-170. J Pediatr
  5. Shipp JC, et al: Treatment of insulin hypoglycemia in diabetic campers. 1964;13:645-648. Diabetes
  6. Aman J, Wranne L: Hypoglycemia in childhood diabetes II: Effect of subcutaneous or intramuscular injection of different doses of glucagon. 1988;77:548-553. Acta Pediatr Scand

Literature revised September 19, 2012

Marketed by: Lilly USA, LLC

Indianapolis, IN 46285, USA

PA 2286 AMP

Copyright © 1999, 2012, Eli Lilly and Company. All rights reserved.

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017